• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antidiabetic drugs and stroke risk. Current evidence.
Abstract Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be responsible for >8% of first ischemic strokes. Therefore, the way to prevent stroke in these patients has become an important issue. Traditionally, glucose-lowering drugs had not been shown to protect against stroke. Moreover, several antidiabetic drugs (i.e., sulfonylureas, rosiglitazone) have been reported to be associated with increased risks of CVD and stroke. On the contrary, data on...
Source: European Journal of Internal Medicine - September 20, 2017 Category: Internal Medicine Authors: Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Carmona-Nimo E Tags: Eur J Intern Med Source Type: research

Pioglitazone: Good news for diabetic patients with stroke?
PMID: 28209458 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - February 12, 2017 Category: Internal Medicine Authors: Castilla-Guerra L, Fernandez-Moreno MD, Colmero-Camacho MA Tags: Eur J Intern Med Source Type: research

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
New England Journal of Medicine,Volume 375, Issue 7, Page 702-704, August 2016.
Source: New England Journal of Medicine - August 16, 2016 Category: Internal Medicine Source Type: research

Diabetes Drug May Stop Stroke, Help Lipids
Pioglitazone may prevent repeated cardiovascular events in some patients. Combined with omega-3 fatty acids, the drug also can improve lipid metabolism.
Source: ConsultantLive - March 1, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Cardiovascular Diseases News Diabetes Source Type: news

VIDEO: Post-stroke pioglitazone modestly protective against secondary vascular events
LOS ANGELES – Nondiabetic, insulin-resistant patients who started pioglitazone within 6 months of an ischemic stroke or transient ischemic attack had almost a 3% absolute risk reduction in secondary...
Source: Internal Medicine News - February 19, 2016 Category: Internal Medicine Source Type: research

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - February 17, 2016 Category: Internal Medicine Tags: article Source Type: research